Efgartigimod, a treatment approved for certain autoimmune diseases, was linked to maintained clinical responses and low disease activity scores for up to 72 weeks in people with Sjögren’s disease, according to data from a small Phase 2 clinical trial and its open-label extension study. Participants who showed a clinical…
Discussion
People with primary Sjögren’s disease and their close family members have a higher risk of developing cancer than the general population, according to a study out of Turkey. While Sjögren’s has been associated with a higher risk of cancer, the potential risk among family members is a new…
Discussion
Through detailed computer-based analyses of publicly available genetic data sets, a team of scientists in China has identified three genes that are overactive in people with Sjögren’s disease, according to a study. The scientists are hopeful that, with further validation, these genes may be used as markers to aid…
Discussion
A global clinical trial testing Immunovant’s injection therapy IMVT-1402 against a placebo in adults with Sjögren’s disease is still recruiting participants, and remains on track to provide initial data in 2028. That’s according to a press release from the company, a Roivant subsidiary, announcing Immunovant’s latest…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
